Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 7/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13003221 | 1.00 | ABCB1 (0.48) | ABCB1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL4659137 | 0.89 | ABCB1 (0.55) | ABCB1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL13003219 | 0.89 | ABCB1 (0.55) | ABCB1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL3769756 | 0.87 | ABCB1 (0.51) | ABCB1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL8617673 | 0.87 | ABCB1 (0.51) | ABCB1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL13003227 | 0.85 | ABCB1 (0.49) | ABCB1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL3778940 | 0.85 | ABCB1 (0.49) | ABCB1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL13003213 | 0.81 | ABCB1 (0.52) | ABCB1CYP3A4 | |
| SCHEMBL3760034 | 0.81 | ABCB1 (0.52) | ABCB1CYP3A4 | |
| SCHEMBL3766544 | 0.81 | ABCB1 (0.51) | ABCB1CYP3A4CYP2C9CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382254-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2016-07-05 | — | — | US | claimed |
| US-8748125-B2 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-06-10 | — | — | US | claimed |
| US-20080214627-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | HORMANN ROBERT EUGENE | 2008-09-04 | — | — | US | claimed |
| US-20080194521-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | HORMANN ROBERT EUGENE | 2008-08-14 | — | — | US | claimed |
| EP-1603860-A4 | DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2008-05-14 | — | — | EP | claimed |
| US-20080103113-A1 | Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand | HORMANN ROBERT E | 2008-05-01 | — | — | US | claimed |
| US-7304161-B2 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide | INTREXON CORPORATION (US) | 2007-12-04 | — | — | US | claimed |
| EP-1603860-A2 | DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene Holdings Inc. (US) | 2005-12-14 | — | — | EP | claimed |
| US-20050209283-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide | ROHM AND HAAS COMPANY | 2005-09-22 | — | — | US | claimed |
| WO-2004072254-A2 | DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE HOLDINGS, INC (US) | 2004-08-26 | — | — | WO | claimed |
| US-9867806-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2018-01-16 | — | — | US | disclosed |
| EP-2994463-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GALAPAGOS NV (BE) | 2017-10-25 | — | — | EP | disclosed |
| US-20170275600-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | INTREXON CORPORATION (US) | 2017-09-28 | — | — | US | disclosed |
| US-9677055-B2 | Modified forms of Pseudomonas exotoxin A | INTERXON CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170037386-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | INTREXON CORPORATION (US) | 2017-02-09 | — | — | US | disclosed |
| WO-2004072254-A2 | DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE HOLDINGS, INC (US) | 2004-08-26 | — | — | WO | disclosed |
| US-6703355-B2 | FIRE RESISTANT PHOSPHATE ESTERS BASE STOCK, A VISCOSITY INDEX IMPROVER, AN ANTICORROSION AGENT, AND ACID SCAVENGER; AIRCRAFT USE | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-20040026566-A1 | Method for lubricating high pressure hydraulic system using phosphate ester hydraulic fluid | ANTIKA SHLOMO (US) | 2004-02-12 | — | — | US | disclosed |
| US-20030060377-A1 | Fire resistant phosphate esters base stock, a viscosity index improver, an anticorrosion agent, and acid scavenger; aircraft use | EXXONMOBIL RESEARCH & ENGINEERING CO. | 2003-03-27 | — | — | US | disclosed |
| WO-2002012777-A2 | METHOD FOR LUBRICATING HIGH PRESSURE HYDRAULIC SYSTEM USING PHOSPHATE ESTER HYDRAULIC FLUID | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214627-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | NR5A2, NR5A1, DECR1 | ABCB1 2143/4885CYP3A4 1955/4885CYP2C9 2488/4885 |
| US-20170275600-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | CD4, CD47, CD14 | ABCB1 2448/4885CYP3A4 4373/4885CYP2C9 4745/4885 |
| US-20080194521-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | NR5A2, NR5A1, DECR1 | ABCB1 2143/4885CYP3A4 1955/4885CYP2C9 2488/4885 |
| US-20080103113-A1 | Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand | NR5A1, NR0B2, NR0B1 | ABCB1 3211/4885CYP3A4 2165/4885CYP2C9 3149/4885 |
| US-20050209283-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide | NR5A2, NR2C2, NR0B2 | ABCB1 2789/4885CYP3A4 2807/4885CYP2C9 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.